Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...

Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

A multiple sclerosis diagnosis used to mean a future of disability. But now, a revolution in medications allows MS patients to pursue their dreams.

The first patient has been dosed in a Phase 1 trial testing the experimental CAR T-cell therapy obecabtagene autoleucel for progressive MS.

The price of Rebif has increased four times faster than the rate of inflation, with Kay's insurer deciding to stop covering ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...